New York, New York (PRWEB) September 18, 2014
As testosterone treatment lawsuits (http://www.injurybeacon.com/testosterone-androgel/lawsuit/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that a panel of experts has recommended that the U.S. Food & Drug Administration (FDA) subject prescription low testosterone therapies to new restrictions that, if implemented, could greatly reduce their use. The joint meeting of the agencys Bone, Reproductive and Urologic Drug Advisory Committee, and the Drug Safety and Risk Management Committee was convened yesterday, as part of the FDAs review of heart risks potentially associated with low testosterone therapy.
According to a report from the Associated Press, the Panel recommended that indications for the medications be limited to men who have abnormally low hormone levels due to disease or injury, instead of aging. They also advised that the labeling for testosterone treatments be revised to clearly state that the medications have not been proven to reduce low libido, fatigue, muscle loss, and other symptoms associated with aging. Finally, while the panelists concluded that evidence of a link between the use of testosterone therapy and cardiovascular problems was inconclusive, they voted overwhelmingly to recommend that the drugs manufacturers be required to conduct long-term studies of their effects on the heart.*
Since the FDA announced its safety review earlier this year, our Firm has heard from numerous men who allegedly suffered heart attacks, strokes and other serious cardiovascular problems due to their use of low testosterone therapy. We now await the agencys final decision on this matter, says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating legal claims on behalf of men who allegedly suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism and other life-threatening heart problems due to their use of prescription testosterone medications.
Court documents indicate that some 200 testosterone treatment lawsuits are now pending in a federal multidistrict litigation now underway in U.S. District Court, Northern District of Illinois. All of the claims were filed on behalf of men who allegedly suffered life-threatening cardiovascular events due to their use of drugs like AndroGel, Axiron and Testim. Among other things, plaintiffs allege that the manufacturers of low testosterone therapies failed to warn doctors and patients about their potential risks, and concealed those dangers from the public. (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)
The FDA launched its review of testosterone treatments in January, after two studies linked the medications to an increased risk of heart attack, stroke and sudden death in certain men. Prior to yesterdays meeting, a briefing document issued by agency reviewers reported that 2.3 million U.S. patients received a prescription for testosterone last year, an increase of 77 percent from 2010. However, the report concluded that there was little evidence to indicate that low testosterone therapy provided any benefits for men who used the drugs to alleviate fatigue, low libido and other symptoms associated with aging.
Victims of heart attacks, strokes, blood clots or other problems allegedly associated with low testosterone therapy may be entitled to compensation or medical bills, lost wages, pain and suffering and more. For more information about filing a testosterone treatment lawsuit, please visit Bernstein Liebhard LLPs website, or call the Firm today at 800-511-5092.
*abcnews.go.com/Business/wireStory/experts-restrictions-testosterone-drug-25577068, Associated Press, September 17, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $ 3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016